Tags

Type your tag names separated by a space and hit enter

Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
BMC Cancer. 2006 May 05; 6:118.BC

Abstract

BACKGROUND

Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm. There are no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP. Therefore, in this large retrospective study, we wanted to assess the outcome, prognostic factors, and the optimal RT dose in patients with SP.

METHODS

Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were collected. Histopathological diagnosis was obtained for all patients. The majority (n = 169) of the patients received RT alone; 32 chemotherapy and RT, and 5 surgery. Median follow-up was 54 months (7-245).

RESULTS

Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and 88%; respectively. Median time to MM development was 21 months (2-135) with a 5-year probability of 51%. In multivariate analyses, favorable factors were younger age and tumor size < 5 cm for survival; younger age for DFS; anatomic localization (vertebra vs. other) for local control. Older age was the only predictor for MM. There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors.

CONCLUSION

Younger patients, especially those with vertebral localization have the best outcome when treated with moderate-dose RT. Progression to MM remains the main problem. Further investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents.

Authors+Show Affiliations

Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. david.knobel@chuv.chNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

16677383

Citation

Knobel, David, et al. "Prognostic Factors in Solitary Plasmacytoma of the Bone: a Multicenter Rare Cancer Network Study." BMC Cancer, vol. 6, 2006, p. 118.
Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.
Knobel, D., Zouhair, A., Tsang, R. W., Poortmans, P., Belkacémi, Y., Bolla, M., Oner, F. D., Landmann, C., Castelain, B., & Ozsahin, M. (2006). Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer, 6, 118.
Knobel D, et al. Prognostic Factors in Solitary Plasmacytoma of the Bone: a Multicenter Rare Cancer Network Study. BMC Cancer. 2006 May 5;6:118. PubMed PMID: 16677383.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. AU - Knobel,David, AU - Zouhair,Abderrahim, AU - Tsang,Richard W, AU - Poortmans,Philip, AU - Belkacémi,Yazid, AU - Bolla,Michel, AU - Oner,Fazilet Dinçbas, AU - Landmann,Christine, AU - Castelain,Bernard, AU - Ozsahin,Mahmut, AU - ,, Y1 - 2006/05/05/ PY - 2006/02/08/received PY - 2006/05/05/accepted PY - 2006/5/9/pubmed PY - 2006/6/29/medline PY - 2006/5/9/entrez SP - 118 EP - 118 JF - BMC cancer JO - BMC Cancer VL - 6 N2 - BACKGROUND: Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm. There are no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP. Therefore, in this large retrospective study, we wanted to assess the outcome, prognostic factors, and the optimal RT dose in patients with SP. METHODS: Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were collected. Histopathological diagnosis was obtained for all patients. The majority (n = 169) of the patients received RT alone; 32 chemotherapy and RT, and 5 surgery. Median follow-up was 54 months (7-245). RESULTS: Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and 88%; respectively. Median time to MM development was 21 months (2-135) with a 5-year probability of 51%. In multivariate analyses, favorable factors were younger age and tumor size < 5 cm for survival; younger age for DFS; anatomic localization (vertebra vs. other) for local control. Older age was the only predictor for MM. There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors. CONCLUSION: Younger patients, especially those with vertebral localization have the best outcome when treated with moderate-dose RT. Progression to MM remains the main problem. Further investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/16677383/Prognostic_factors_in_solitary_plasmacytoma_of_the_bone:_a_multicenter_Rare_Cancer_Network_study_ L2 - https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-6-118 DB - PRIME DP - Unbound Medicine ER -